Calidi Biotherapeutics -CW23CLDWWPreferred / convertible
13F holders, Q4 2024 (December 31)1holders −14
0new positions
14sold out
$0.01avg. 13F price*
At the end of Q4 2024, 1 institutions reported holding Calidi Biotherapeutics -CW23 (CLDWW) in their 13F filings, down 14 from Q3 2024. 0 opened new positions and 14 sold out. The largest holder was Exos Asset Management LLC ($1K).
- Company
- Calidi Biotherapeutics -CW23
- CUSIP
- 320703119
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 14 | $75K |
All 13F filers, Q3 2024 → Q4 2024: 5,613,417 shares sold, net −5,613,417 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Exos Asset Management LLC | — | No change | 105,000 | $1K |
"% of holder's portfolio" is CLDWW's weight in each manager's 13F, not the share of Calidi Biotherapeutics -CW23 the manager owns.